Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Amgen
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...
Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China
China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...
Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...